Mutations in the mitochondrial complex IV assembly factor SURF1 represent a major cause of Leigh syndrome (LS), a rare fatal neurological disorder. SURF1-deficient animals have failed to recapitulate the neuronal pathology of human LS, hindering our understanding of the disease mechanisms. We generated induced pluripotent stem cells from LS patients carrying homozygous SURF1 mutations (SURF1 iPS) and performed biallelic correction via CRISPR/Cas9. In contrast to corrected cells, SURF1 iPS showed impaired neuronal differentiation. Aberrant bioenergetics in SURF1 iPS occurred already in neural progenitor cells (NPCs), disrupting their neurogenic potency. Cerebral organoids from SURF1 iPS were smaller and recapitulated the neurogenesis defects. Our data imply that SURF1 mutations cause a failure in the development of maturing neurons. Using NPC function as an interventional target, we identified SURF1 gene augmentation as a potential strategy for restoring neurogenesis in LS patients carrying SURF1 mutations.
Introduction
Leigh syndrome (LS, OMIM #256000) is a rare genetic neurological disorder characterized by symmetric lesions in the central nervous system (CNS), particularly in the basal ganglia and brain stem, and by psychomotor regression and lactic acidosis 1 . The symptoms typically manifest during the first year of life, with congenital onset occurring in one fourth of the cases 2 . The disease is fatal with a course that is variable but usually severe, and has a peak of mortality before the age of three 3 . LS is a genetically heterogeneous disease with pathogenic variants identified in more than 60 genes 4 . All of the affected genes are directly or indirectly involved in the maintenance of mitochondrial oxidative phosphorylation (OXPHOS), making LS one of the most prevalent mitochondrial disorders affecting 1/36,000 newborns 5 .
Recessive mutations in SURF1 occur in about one third of all LS cases and represent the single most common cause of LS [6] [7] [8] . SURF1 encodes the highly-conserved protein Surfeit locus protein 1 (SURF1), which is located in the inner mitochondrial membrane and is involved in the assembly of mitochondrial complex IV, i.e. the cytochrome C oxidase (COX) 9 . COX is the terminal enzyme of the electron transport chain catalyzing the transfer of electrons from cytochrome C to molecular oxygen. COX is composed of 13 subunits, three of which (MT-CO1, MT-CO2, MT-CO3) are encoded by the mitochondrial DNA (mtDNA) and constitute the hydrophobic catalytic core that is assembled first during formation of the complex 10 .
The molecular mechanisms underlying the neurological impairment caused by SURF1 defects in humans remain poorly understood. Consequently, there are currently no pathogenicity-based treatments available for affected patients 11, 12 . An important obstacle in our understanding of the disease pathogenesis is the paucity of adequate model systems 13 .
SURF1 knock-out mice failed to recapitulate the neurological phenotypes seen in humans and even led to prolonged lifespan, despite the presence of COX defects and mild lactic 4 acidosis 14, 15 . In Drosophila melanogaster, CNS-specific knock-down of SURF1 increased longevity and did not produce neurological defects, while constitutive SURF1 knock-down resulted in embryonic lethality 16 . SURF1 knock-down in zebrafish caused reduced COX activity and developmental defects in endodermal tissue with a neurological impairment mainly occurring at the level of motoneurons and the peripheral nervous system 17 . SURF1
knock-out in piglets resulted in a severe lethal phenotype but the neurological defects were mild, mainly comprising a slight delay of CNS development without lactic acidosis and without apparent COX deficiency 18 .
In order to dissect the molecular mechanisms underlying the neuronal pathology in LS patients carrying homozygous SURF1 mutations (LS SURF1 ), we generated induced pluripotent stem cells from LS SURF1 patients (SURF1 iPS). Neuronal cultures and cerebral organoids derived from SURF1 iPS exhibited features indicative of impaired neurogenesis. Bioenergetic dysfunction occurred already at the level of neural progenitor cells (NPCs), and led to defects in neuronal generation and maturation, disrupting the branching capacity and firing activity of neurons. Biallelic correction of SURF1 mutation via CRISPR/Cas9 genome editing reverted the phenotypes. Our data imply that LS SURF1 causes a failure in the development of maturing neurons. We employed NPC function as an interventional target and discovered that wild-type SURF1 over-expression was effective in improving NPC bioenergetics and promoting neurogenesis. Altogether, we propose aberrant neurogenesis as a central pathogenetic mechanism in LS SURF1 and suggest a potential strategy for restoring neuronal function in this fatal pediatric disease.
Results

Genetic repair in SURF1 iPS restores COX activity
We obtained skin fibroblasts from two LS SURF1 patients belonging to two distinct consanguineous families: S1A carrying the homozygous mutation c.530T>G (p.V177G), and 5 S1C carrying the homozygous mutation c.769G>A (p.G257R) (Fig. S1) . We used Sendai virus-based reprogramming to generate the respective SURF1 iPS lines SVS1A and SVS1C, which we confirmed to be pluripotent ( Fig. 1a ; Fig. S2a-b ; Fig S2e) while still harboring the parental SURF1 mutations on both alleles ( Fig. 1a; Fig. S2c-d) .
We corrected the c.769G>A mutation on both alleles in SVS1C using clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 and obtained SVS1C-corrected cells (SVS1C.C) ( Fig. 1b-d ; Fig. S3a-b) . We achieved genetic correction using high-fidelity eCas9, which has limited off-target effects 19 , and by including plasmids expressing RAD52 and dominant negative p53-binding protein 1 (dn53BP1) in order to promote homologous direct repair (HDR) and inhibit non-homologous end joining (NHEJ) 20 ( Fig. S3a ). In the HDR template, we introduced two silent mutations that we could trace in the sequences of the SVS1C.C clones (3p and 3bb) to confirm the faithful correction of the mutation (Fig. 1b-c) . The corrected lines retained features of pluripotency ( Fig. 3d ; Fig. S3c) and had normal karyotypes (Fig. S3e) .
We monitored COX activity in NPCs derived from SURF1 iPS (SVS1A and SVS1C) and from genetically corrected iPSCs (SVS1C.C, clones 3p and 3bb). We determined the protein abundance of the MT-CO2 subunit, a key component of the COX enzyme catalytic core, and the enzymatic activity of the entire COX complex. In NPCs from SVS1A and SVS1C, MT-CO2 protein was almost undetectable (Fig. 1e) and COX activity was very low (Fig. 1f) . In contrast, NPCs derived from CRISPR/Cas9-corrected SVS1C.C lines reexpressed MT-CO2 ( Fig. 1e ) and had their COX activity restored (Fig. 1f) . The activity of complex II succinate dehydrogenase (SDH) remained similar in all NPCs (Fig. 1f) ,
confirming that the defects in SURF1-mutant cells were specific for complex IV. Overall, the findings demonstrated that the mutation repair in SVS1C.C had led to functional recovery of SURF1-mediated COX assembly.
SURF1 mutations impair the generation of neuronal cells
In order to address the influence of SURF1 mutations on the development and function of human neurons, we differentiated all induced pluripotent stem cells (iPSCs) into functional neuronal cultures that were enriched for midbrain dopaminergic (DA) neurons 21 (Figs. 2a;
S4a-c), as degeneration of DA neurons is thought to cause the predominant basal ganglia pathology seen in LS patients ( Fig. S1a-f ) 22 . Besides neurons, the cultures contained mature astrocytes ( Fig. 2a) , which are important CNS sources of lactate 23 , whose levels are increased in the liquor and serum of most LS patients 11 .
We assessed DA cultures at 4 weeks (4w) and 8 weeks (8w) after differentiation from
NPCs. We found a reduction in the numbers of neurons in DA cultures obtained from SURF1
iPS as compared to DA cultures derived from healthy induced pluripotent stem cells (CTRL iPS) or from human embryonic stem cells (CTRL ES) (Fig. 2b ). Mutation correction in SVS1C.C restored neuronal differentiation (Fig. 2b) , confirming that SURF1 mutations specifically impaired neurogenesis. DA cultures from SVS1A and SVS1C showed a reduced amount of NCAM-positive neuron-restricted progenitors compared to cultures from CTRL ES and CTRL iPS (Fig. 2c) . Conversely, the number of A2B5-positive glial-restricted progenitors did not change (Fig. 2c ). The number of cells positive for the astrocyte marker GLAST was also unchanged ( Fig. S4d-f ). Astrocyte-derived cytokines 24 increased over time in mature cultures but did not exhibit significant differences between LS SURF1 patients and controls (Table S1 ). Taken together, SURF1 mutations affected neuronal production possibly through defects of neurogenesis arising at the level of neuron-committed NPCs.
We performed transcriptome analysis of 4w and 8w DA cultures from SURF1 iPS, CTRL iPS, and CTRL ES using polyA mRNA-sequencing ( Fig. S5a ) and of 4w and 8w DA cultures from SVS1C and SVS1C.C using ribo-zero total RNA-seq (Fig. S5a ). There was a strong correlation between the two datasets and we focused on the genes and pathways that were consensually differentially regulated in both settings. Downregulated genes in SURF1-mutant 4w DA cultures included genes involved in neurogenesis and nervous system development such as NKX2-2, FOXA1, FOXA2, and NCAM2 ( Fig. 2d ; Fig S5b ; Table S2;   Table S4 ), as well as genes important for axonal outgrowth and synaptic signaling like SPON1 and CNTN4 ( Fig. 2d ; Fig. S5c-d ; Table S2 ; Table S4 ). The downregulation of genes regulating synaptic function (SYP, SYT13, KCNC2) and axon guidance (ARX, NTN1) in SURF1-mutant cultures became even more evident at 8 weeks of differentiation ( Fig. 2e ; Fig. S5b-d; Table S3 ; Table S4 ). At the same time, SURF1-mutant DA cultures at 4w and 8w
upregulated genes associated with embryonic development and pluripotency such as MYC, LIN28A, POU5F1, USP44, DPPA3, and DPPA4 ( Table S2 ; Table S4 ). At the beginning of differentiation, neuronal cells have increased energy demands and may thus attempt to compensate their COX deficiency through augmented expression of components of the catalytic core of COX enzyme. However, upon prolonged differentiation this compensatory mechanism may be shut down as it becomes insufficient. Accordingly, 8w
neuronal cultures from SURF1 iPS downregulated PPRGC1A (PGC1A) ( Fig. 2e; Fig. 3a ;
Fig. S6a; Table S3; Table S4 ), a master activator of mitochondrial biogenesis and OXPHOS metabolism that is important for neuronal maturation 25, 26 . SURF1 iPS 8w DA cultures also downregulated PDK3 and PDK4 ( Fig. 2e; Fig. 3a ; Fig. S6a ; Table S3; Table S4 ), which are 8 negative regulators of glucose oxidation and crucial for maintaining energy homeostasis 27, 28 .
At the same time, 4w and 8w DA cultures from SURF1 iPS showed increased expression of glycolysis-promoting lactate dehydrogenase enzymes LDHA and LDHD ( Fig. 3a; Fig. S6a ).
Taken together, maturing neuronal cultures carrying SURF1 mutations might fail to activate mitochondrial metabolism over time and therefore retain features of glycolytic metabolism.
In order to dissect the functional consequences of SURF1 mutations on cellular bioenergetics, we investigated the oxygen consumption rate (OCR) in living cells. We did not observe differences between LS SURF1 patients and controls at the level of somatic fibroblasts ( Fig. 3 ; Fig. S6b; Fig S6i) or iPSCs ( Fig. 3c; Fig. S6c; Fig. S6j ). On the other hand, SURF1-mutant neural cells exhibited significantly reduced mitochondrial respiration (basal OCR, maximal respiration, and ATP production) ( Fig. 3d ; Fig. S6d-g ). Mitochondrial bioenergetics was restored upon mutation correction in SVS1C.C-derived neural cells ( Fig. 3e-f ; Fig. S6d-f ; Fig. S6h ). Bioenergetic defects were present throughout neuronal differentiation but became biochemically apparent already at the level of NPCs ( Fig. 3d-f ; Fig. S6d ; Fig. S6g-h ). When compared to isogenic control cultures, 8w DA cultures from SVS1C produced an increased amount of glycolysis-derived lactate, a pathognomonic feature of LS (Fig. 3g-h ).
Overall, the bioenergetic assessments supported our observation that SURF1 mutations interfere with the function of NPCs, which may in turn affect the functionality of differentiated neurons.
We assessed the consequences of the bioenergetic defects in differentiated neurons through quantification of mitochondrial movement. SVS1C-derived DA cultures showed an abnormal increase in mitochondrial motility in comparison to SVS1C.C cultures ( Fig. 3i; Suppl. video 1-4), causing a significantly reduced number of stationary mitochondria (Fig.   3j ). Stationary mitochondria are crucial for axonal branching and synaptic homeostasis 29, 30 .
Hence, the disruption of mitochondrial bioenergetics and motility in SURF1-mutant cultures might negatively affect the branching and firing capacity of differentiating neurons.
SURF1 mutations disrupt neuronal branching and activity
We investigated whether the defects observed in SURF1-mutant NPCs altered not only the number of neurons and their metabolic properties, but also in their firing capacity. Patchclamp analysis demonstrated that differentiating neurons from controls and patients matured over time, as indicated by their passive membrane properties showing time-dependent increase in cell capacitance (as neurons increase in size) (Fig. S7a) and decrease in input resistance (as neurons acquire more ion channels in their plasma membrane) (Fig. S7b) .
However, the active membrane properties of neurons (i.e. electrical potentials across the plasma membrane activated by voltage, ligands, or second messengers) differed between patients and controls. We observed a significant increase in sodium and potassium currents at 8w compared to 4w in neurons derived from CTRL iPS (Fig. 4a) and from CTRL ES ( Fig   S7d) . This increase in currents at 8w was less pronounced in neurons differentiated from SURF1 iPS (Fig. 4b) . Neurons from SURF1 iPS also contained a higher number of nonspikers and a lower number of multiple-spikers as compared to neurons from CTRL iPS ( (Fig. 4d ) and at 8w (Fig. 4e) . Neurons from SVS1C.C also contained a lower number of non-spikers and a higher number of multiple-spikers than neurons from SVS1C at 4w (Fig. S7c ) and at 8w ( Fig. 4f; Fig S7e) . Moreover, SVS1C.C neurons exhibited post-synaptic currents indicative of synaptic activity, which we could not observe in SVS1C neurons (Fig. 4g) .
We next addressed the capacity of neurons to generate branches using high-content analysis (HCA)-based quantification of neurite length per neuron and branching points per neuron. Neurite outgrowth was significantly lower in neurons from SURF1 iPS than in neurons from CTRL iPS (Fig. 4h-i) . This was particularly evident in 8w DA cultures.
Correction of SURF1 mutation in SVS1C.C neurons restored the neuronal complexity in neurites and branching patterns (Fig. 4j-l) . Altogether, SURF1 mutations impaired the functionality of maturing neurons by disrupting their firing properties and their ability to establish synaptic connections.
Neurogenesis defects in SURF1-mutant cerebral organoids
Since monolayer cultures do not allow studying the manifestation of spatial defects, we employed a three-dimensional (3D) model of neuronal development (Fig. S8a-b) to explore the consequences of SURF1 mutations on organogenesis. Cerebral organoids derived from SVS1C were significantly smaller than organoids differentiated from the isogenic control SVS1C.C (clones 3p and 3bb) ( Fig. 5a-b; Fig. S8c ). SVS1C organoids exhibited a dramatic disruption of the neuroepithelial layer surrounding fluid-filled cavities that are reminiscent of embryonic ventricles ( Fig. 5c; Fig. S8d ). These macroscopic phenotypes pointed towards neurodevelopmental defects caused by impaired neurogenesis.
In agreement with a neurogenic defect, SVS1C organoids showed downregulated expression of genes involved in neurogenesis like NKX2.2, CDX, LHX2, and GATA3, of genes regulating axon guidance like ARX, NTN1, and SPON1, and of genes associated with neuronal firing and synaptic activity like SYP, SYT3, KCNQ2, and SCN7A (Fig. 5d ). SVS1C organoids also showed reduced expression of genes regulating mitochondrial metabolism like PGC1A
and PDK4, while the expression of genes associated with glycolysis such as MYC and LDHA increased in comparison to isogenic control SVS1C.C organoids (Fig. 5d) . Overall, the transcriptional profile of brain organoids was in line with the transcriptional profile of the two-dimensional (2D) neuronal cultures ( Fig. 2d-e ; Fig. S5b-e; Fig. S6a ).
We then investigated the microscopic cytoarchitecture of the organoids. SURF1
mutations altered the 3D self-organizing capacity of the cells and led to disrupted neuronal layering and reduced cortical thickness (Fig. 5e) . SVS1C organoids showed aberrant distribution of the NPC marker SOX2 ( Fig. 5e; Fig. S8f ) and of the neuronal marker TUJ1 (Fig. 5e) , while the expression of astrocyte marker S100ß appeared mainly unaltered (Fig.   S8e) . Altogether, the 3D model recapitulated the defects observed in the monolayer cultures and confirmed that SURF1 mutations impair the neural progenitor state, thereby disrupting the process of neurogenesis.
Targeting NPC function allows the identification of SURF1 gene augmentation as potential therapeutic strategy
Given the possible importance of dysfunctional neurogenesis in the pathogenesis of LS SURF1 , we asked whether targeting NPC function could be of therapeutic benefit. We and others have previously employed iPSC-derived NPCs for identifying treatment interventions in the context of neuropsychiatric and mitochondrial diseases 31, 32 . In comparison to isogenic control SVS1C.C-NPCs, SURF1-mutant SVS1C-NPCs showed bioenergetics defects, including reduced oxygen consumption (Fig. 6a ) and increased lactate production (Fig. 6b) .
Neuronal profiling of NPC cultures revealed that early neurons within SVS1C-NPC cultures exhibited smaller neurites (Fig. 6c ) and less branching points (Fig. 6d) We evaluated potential therapeutic strategies by measuring their ability to restore the functional and metabolic features of SURF1-NPCs. We first focused on interventions
targeting OXPHOS activity. We tested: (i) the antioxidant α-Tocotrienol (AT3), whose in vivo-derived metabolite EPI-743 has been suggested as a therapy for LS 33 , (ii) fibroblast growth factor 21 (FGF21), which regulates glucose metabolism and promotes PGC1-α expression in human DA neurons 34, 35 , (iii) glucose supplementation, is suggested for LS patients during acute metabolic decompensation 36 , and iv) pyruvate supplementation, which has been proposed as treatment for LS caused by COX defects 37 . We did not detect any consistent improvement of the phenotypes in NPCs exposed to these OXPHOS-centered interventions ( Fig. S9a-d) .
We then cultured NPCs under hypoxic conditions, which had shown functional benefit in animal models of LS with knock-out of the complex I gene NDUFS4 38 . Overnight culture under hypoxia (5% oxygen) significantly improved mitochondrial respiration in SURF1-NPCs ( Fig. 6e; Fig. S9i-j) . At the same time, however, hypoxia caused an undesired further increase in lactate production in SVS1C-NPCs (Fig. 6f) , reduced OCR in control SVS1C.CNPCs ( Fig. S9e-f) , and negatively affected neurogenesis in NPCs derived from both SVS1C
( Fig. 6g-h ) and SVS1C.C (Fig. S9g-h ).
Next, we transduced SVS1C with a lentiviral vector encoding wild-type SURF1 to assess the potential rescuing effect of SURF1 overexpression (SURF1-OE). In comparison to SVS1C transduced with lentiviruses encoding only the GFP derivative mCitrine (GFP), SURF1-OE showed significantly improved mitochondrial respiration (Fig. 6e) leading to a significant reduction of lactate production (Fig. 6f) . Moreover, SURF1-OE improved the branching complexity of early neurons (Fig. 6g-h ).
In conclusion, we used NPC function as a readout for interventions and found that SURF1-OE was beneficial in restoring bioenergetics and promoting neurogenesis. We thus propose SURF1 gene augmentation therapy (GAT) as a potential strategy for restoring the neuronal function in LS SURF1 patients (Fig. S9k) .
Discussion LS SURF1 has generally been considered an early-onset neurodegenerative disease.
However, the mechanistic and pathophysiological understanding of LS SURF1 is hindered by the lack of effective model systems. SURF1 knock-out has been carried out in several animals (flies, mice, zebrafish, and piglets) but all these efforts failed to fully recapitulate the 40 .
The dysfunction of SURF1-mutant NPCs might be related to their specific metabolic properties. Neurogenesis encompasses a series of complex cell fate transitions culminating in the terminal differentiation of NPCs into neurons. This process is accompanied by a metabolic shift from glycolysis to mitochondrial-based oxidative metabolism 41, 42 . NPCs may represent the first cell type during this course to depend on mitochondrial oxidative function.
Mitochondrial metabolism is in fact essential in mice for both embryonic and adult neurogenesis 43, 44 . Moreover, we previously demonstrated that human iPSC-derived NPCs activate the OXPHOS machinery and are equipped with functionally mature mitochondria 31 .
Should mitochondrial bioenergetics be impaired during brain development, NPCs might thus be the first cell population to be negatively affected. The dependence of cell type-specific function on different ATP-generating pathways might also explain the apparent absence of functional defects in astrocytes, given the fact that glial cells mainly rely on glycolytic metabolism 45, 46 .
Our findings may open the way to new therapeutic avenues for LS focusing on improving neurogenesis rather than preventing the degeneration of fully functionally neurons.
The current understanding that LS is caused by early-onset neurodegeneration had led to experimental treatment schemes centered around antioxidants to prevent the build-up of damaging free radicals 11, 12 . However, blocking oxidative damage may not be sufficient in restoring neurogenesis. Antioxidant regiments may also dampen the physiological effect of radicals signaling, thereby blunting compensatory responses 47 . Other suggested treatment strategies aim at providing energy support through glucose or pyruvate administration 36, 37 .
But the need for bioenergetic restoration may not be uniform across all OXPHOS-dependent cell types. In LS SURF1 , for example, muscle cells do not usually show the same level of impairment as neuronal cells 2 . Conversely, mutations in the gene encoding SCO2, which is a different assembly factor of COX, more strongly impair cardiac bioenergetics leading to cardiomyopathy rather than LS 48 . Hence, instead of general metabolic interventions, we propose that therapeutic strategies for LS SURF1 should specifically focus on improving neuronal metabolism.
Using NPC function as an interventional target, we discovered that overexpression of wild-type SURF1 restored neurogenesis in SURF1-mutant cells. There are ongoing clinical trials on gene augmentation therapy (GAT) for CNS disorders 49 . GAT also ameliorated the LS-like phenotypes in the complex I gene NDUFS4 knock-out mice 50 . Given the proposed impairment of neurogenesis, we think that GAT in LS SURF1 should be carried out as early as possible to enable the formation of functional neurons and neuronal networks in the patients.
Further studies are needed to investigate in details the potential adverse reactions of SURF1-GAT in live animals and to identify the most effective strategy with respect to viral vector types, timing, and sites of delivery.
In conclusion, we generated the first human mechanistic models of LS SURF1 , which enabled us to discover that SURF1 defects impair neurogenesis and led us to propose early-15 initiated SURF1-GAT as a potential therapeutic strategy for counteracting the neurodevelopmental failure in this fatal neuropediatric disorder.
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